Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

NCT01343498 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: BEZ235

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]